Argenx
ARGX
#402
Rank
A$87.94 B
Marketcap
A$1,399
Share price
-1.73%
Change (1 day)
-1.38%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2026 (TTM): A$2.76 Billion

According to Argenx 's latest financial reports the company's current earnings are A$5.82 Billion. In 2025 the company made an earning of A$1.93 Billion, an increase over its 2024 earnings that were of A$0.12 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$2.76 B43.02%
2025 A$1.93 B1400.58%
2024 A$0.12 B-127.97%
2023 -A$0.47 Billion-58.25%
2022 -A$1.11 Billion80.17%
2021 -A$0.62 Billion
2019 -A$0.31 Billion124.86%
2018 -A$0.14 Billion131.81%
2017 -A$57.64 Million
2015 -A$27.83 Million
2013 -A$16.84 Million